Company · Public · 3696.HK

Insilico Medicine

Generative chemistry and target discovery company with clinical assets originating from its AI platform.

Listing

Public

Ticker

3696.HK

Headquarters

Hong Kong / Boston

Founded

2014

Technology

Generative AI drug discovery

Longevity thesis

If AI-originated molecules read out positively in humans, discovery cost per aging-related target falls materially.

Programmes

RentosertibPhase 2
Idiopathic pulmonary fibrosis
Aging target portfolioDiscovery
Fibrosis and senescence

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.